Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

liabilityinjunctionappealpatent
injunctionappealpatent

Related Cases

Hanly v. Kleindienst, 471 F.2d 823, 4 ERC 1785, 2 Envtl. L. Rep. 20,717
View Case »
Pointer v. Six Wheel Corp., 177 F.2d 153, 83 U.S.P.Q. 43
View Case »
Cooper v. Goldfarb, 154 F.3d 1321, 47 U.S.P.Q.2d 1896
View Case »
Okajima v. Bourdeau, 261 F.3d 1350, 59 U.S.P.Q.2d 1795
View Case »
Freedman Seating Co. v. American Seating Co., 420 F.3d 1350, 76 U.S.P.Q.2d 1001
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 42 U.S.P.Q.2d 1001

Facts

The specification indicates that it purports to solve a problem. That problem is summarized at column 3, line 65, through column 4, line 8: [A] need has existed for new methods of producing hGH and other polypeptide products in quantity and that need has been particularly acute in the case of polypeptides too large to admit to organic synthesis or, for that matter, microbial expression from entirely synthetic genes.

Issue

Was the patent for the cleavable fusion expression process for producing human growth hormone (hGH) valid, and did the district court err in granting a preliminary injunction?

Was the patent for the cleavable fusion expression process for producing human growth hormone (hGH) valid, and did the district court err in granting a preliminary injunction?

Rule

The grant or denial of a preliminary injunction is within the discretion of the district court, which must consider four factors: (1) a reasonable likelihood of success on the merits; (2) irreparable harm if the injunction is not granted; (3) the balance of hardships; and (4) the impact of the injunction on the public interest. A patent is presumed valid, but the patentee must demonstrate a likelihood of success on all disputed liability issues, including validity.

Analysis

The Court of Appeals found that the district court erred in its conclusion that Genentech had demonstrated a likelihood of success on the merits. The court determined that the specification of the patent did not enable a person skilled in the art to practice the claimed invention without undue experimentation, thus rendering the patent invalid. The court emphasized that the specification must provide sufficient detail to enable the claimed invention, which was not met in this case.

The question before us is whether the specification would have enabled a person having ordinary skill in the art at the time of filing to use cleavable fusion expression to make hGH without undue experimentation.

Conclusion

The Court of Appeals vacated the preliminary injunction and held that the patent was invalid for failure of specification to enable the practice of the claimed method.

We therefore hold that claim 1 and hence the '199 patent are invalid as a matter of law for failure of the specification to enable the practice of the claimed method.

Who won?

Novo Nordisk A/S prevailed in the appeal against Genentech, as the Court of Appeals found that the patent was invalid due to a lack of enabling disclosure. The court determined that the district court had abused its discretion in granting the preliminary injunction based on an erroneous legal conclusion regarding the likelihood of success on the merits.

Novo Nordisk A/S prevailed in the appeal against Genentech, as the Court of Appeals found that the patent was invalid due to a lack of enabling disclosure.

You must be